GlassScriptPhysician profile
John T Mays
NPI 1689678484
$39,571.51
in general payments reported to CMS, 2019-2025
36 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,836 · 2020: $2,732 · 2021: $18K · 2022: $16K · 2023: $420 · 2024: $363 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $32,103.44 | 2021-2022 | |
| Midsouth Orthopedics INC. | $1,603.76 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $1,194.33 | 2020-2023 | |
| Arthrex, INC. | $618.17 | 2020 | |
| Depuy Synthes Sales INC. | $518.38 | 2020-2023 | Fibergraft Bg Morsels |
| Stryker Corporation | $516.64 | 2020-2025 | Axsos, Gamma |
| Conformis, INC. | $407.99 | 2019 | |
| Smith+Nephew, INC. | $392.04 | 2019-2025 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Allevyn Heel 10.5cm X 13.5cm Ctn 5, Collagenase Santyl |
| Pacira Therapeutics, INC. | $293.90 | 2019-2021 | |
| Horizon Therapeutics Plc | $216.91 | 2019-2021 | |
| Medtronic USA, INC. | $195.15 | 2019-2020 | |
| Medtronic, INC. | $185.19 | 2021-2025 | Aquamantys(Tm), Intellis Adaptivestim |
| Wright Medical Technology, INC. | $152.79 | 2019 | |
| Sanara Medtech INC. | $150.11 | 2021 | |
| Ethicon US, LLC | $147.61 | 2019-2024 | Ethicon, Proximate, Echelon Flex |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $137.83 | 2020-2021 | |
| Axogen | $110.57 | 2021-2025 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Protector |
| Astrazeneca Pharmaceuticals LP | $76.91 | 2019 | |
| Dynasplint Systems INC. | $75.30 | 2023-2025 | Dynasplint |
| Vertex Pharmaceuticals Incorporated | $70.50 | 2024-2025 | |
| Fidia Pharma USA INC. | $46.34 | 2019-2020 | |
| Si-Bone, INC. | $38.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $37.49 | 2019 | |
| Mallinckrodt Enterprises LLC | $32.97 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $29.24 | 2022-2023 | Iovera, Exparel, Zilretta |
| Bioventus LLC | $28.71 | 2025 | Durolane |
| Davol INC. | $28.31 | 2025 | Avitene Ultrafoam |
| Vericel Corporation | $27.86 | 2023-2024 | Maci |
| Innovation Technologies INC | $24.34 | 2024 | Irrisept |
| Abbvie INC. | $21.76 | 2023 | |
| Kci USA, INC. | $18.62 | 2022 | |
| Heraeus Medical, LLC. | $16.87 | 2025 | |
| Amgen INC. | $16.02 | 2022 | |
| Baudax Bio INC. | $14.41 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.45 | 2021 | |
| Ferring Pharmaceuticals INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.